RxDoctor Payments Data

Sunitha Bollineni, MD

Internal Medicine · Rochester, NYNPI 1326185166

Payments from drug & device makers

$3,441in general payments, 2019–2025

Across 238 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$686
  • AbbVie$608
  • Pfizer$463
  • GSK$341
  • Amarin Pharma, Inc.$280
  • Johnson & Johnson$229
  • plus $834 from 11 others

What the payments were for

  • Food & beverage$3,441100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,441 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$36,985
Medicare patients
143
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$141,450
EliquisApixaban70$87,160
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$46,635
JardianceEmpagliflozin33$39,757
TradjentaLinagliptin26$36,725
MounjaroTirzepatide27$34,392
JanuviaSitagliptin Phosphate23$33,579
FarxigaDapagliflozin Propanediol21$21,665
TrulicityDulaglutide11$18,780
XareltoRivaroxaban14$15,973
EntrestoSacubitril/Valsartan21$15,881
RybelsusSemaglutide12$15,364
LinzessLinaclotide15$13,466
SymbicortBudesonide/Formoterol Fumarate47$12,662
Breo ElliptaFluticasone/Vilanterol20$12,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$686$156,814146 claims
PfizerEliquis, Paxlovid$463$91,02182 claims
GSKTrelegy Ellipta, Breo Ellipta$341$58,92386 claims
Lilly USA, LLCMounjaro, Trulicity$202$53,17238 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$194$42,59581 claims
MerckJanuvia$70$33,57923 claims
AbbVieLinzess, Synthroid$608$16,11336 claims
Johnson & JohnsonXarelto$229$15,97314 claims
NovartisEntresto$130$15,88121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →